Prévisions
L'objectif de cours moyen des analystes est de 7,59 € (+0,93 %). La médiane est de 7,29 € (-3,06 %).
| Acheter |
6 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
DiaMedica Q2 loss in line with guidance; clinical programs make progress
DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » Plus sur de.investing.com
1 Main Capital highlights DiaMedica Therapeutics for DM199 stroke‑recovery potential
1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » Plus sur finance.yahoo.com
DiaMedica Therapeutics strengthens liquidity and reports slightly better EPS for Q4 2025
DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » Plus sur de.investing.com
DiaMedica receives Health Canada approval for phase-2 study of DM199 in early-onset preeclampsia
DiaMedica has received a 'No Objection Letter' from Health Canada to start an open-label phase-2 dose-finding study of DM199 in early-onset preeclampsia. The study, planned for 2026, will test three dose levels, administer DM199 subcutaneously every three days until delivery, and assess safety, tolerability and exploratory efficacy markers such as pulsatility index, sFlt‑1 and placental growth factor. The company plans to expand the study to the US and the UK after regulatory clearances. According to the data, DiaMedica shows high short-term liquidity; analysts have price targets between $11 and $25, while InvestingPro currently considers the stock overvalued. » Plus sur de.investing.com
DiaMedica must conduct additional non-clinical study for DM199 after FDA talks
The FDA requires, before an IND filing for treatment of early-onset preeclampsia, a 10-day modified embryo‑fetal plus pre- and postnatal study in rabbits, with results expected by Q2 2026. DiaMedica announced it will carry out this study for its drug DM199 (Rinvecalinas‑Alfa) and said the talks provided regulatory clarity on the non-clinical data package. At the same time, an investigator-initiated phase‑2 trial in South Africa is already treating more than 30 women with late-stage preeclampsia; preliminary data show encouraging safety and efficacy signals. Analysts have lowered their earnings estimates following the news, and the stock has recently fallen. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2022, DIAMEDICA THERAPEUT. a déjà versé 2,74 € de dividendes. Le dernier versement a eu lieu en mars 2022.
Données financières
Au dernier trimestre, DIAMEDICA THERAPEUT. a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -9,99 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -9,99 M | 35,94 % |
| EBITDA | -9,97 M | 36,08 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 405,69 M € |
Nombre d'actions | 53,96 M |
Plus haut/bas sur 52 semaines | 10,02 € - 4,78 € |
| Dividendes | Non |
Bêta | 0,94 |
Ratio P/E | -10,86 |
Ratio PEG | 1,57 |
Ratio P/B | 15,53 |
Ratio P/S | 0,00 |
Profil de l'entreprise
DiaMedica Therapeutics Inc., une société biopharmaceutique au stade clinique, développe des traitements contre les maladies neurologiques et rénales. Le candidat-médicament principal de la société est le DM199, une protéine recombinante de kallikréine-1 tissulaire humaine, qui est en essai de phase 2 REDUX pour le traitement des patients atteints d'une maladie rénale chronique modérée ou sévère causée par le diabète de type I ou de type II ; et en essais de phase 2/3 REMEDY2 pour le traitement des patients atteints d'un accident vasculaire cérébral ischémique aigu. La société développe également le DM300, qui est au stade précclinique pour le traitement des maladies inflammatoires. La société était anciennement connue sous le nom de DiaMedica Inc. et a changé sa dénomination en DiaMedica Therapeutics Inc. en décembre 2016. DiaMedica Therapeutics Inc. a été constituée en 2000 et son siège social se trouve à Minneapolis, dans le Minnesota.
| Nom | DIAMEDICA THERAPEUT. |
| PDG | Dietrich John Pauls |
| Siège social | Minneapolis,
mn États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 03/08/2012 |
| Employés | 35 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | DMAC |